Top Biotech Gainers: CELZ Soars On Patent News, BRVE Debuts Strong, IOVA Revenue Climbs 66%

Today's top gainers in the biotech space include Creative Medical, boosted by a new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes; Braveheart, following its IPO; Iovance, after reporting a 66% increase in second-quarter revenue; and Sight Sciences, after raising its full-year outlook following strong quarterly performance, among others.

Read on...

CELZ's Patent Expansion Sparks Investor Interest

Creative Medical Technology Holdings Inc. (CELZ) led the pack of gainers on Thursday, with shares rising more than 70% on patent news.

This clinical-stage biotechnology company advancing regenerative medicine solutions announced it has received a new U.S. patent covering exosome-based immunotherapy for Type 1 diabetes. The patent expands the company's intellectual property protection for its MyeloCelz, CELZ-101, and CELZ-201 diabetes platforms.

CELZ closed Thursday's trading at $1.15, up 71.95%.

BRVE Debuts with a Bang

Braveheart Bio Inc. (BRVE) jumped more than 65% on its first day of trading on the Nasdaq.

This clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ("HCM") and other serious cardiovascular diseases made its Nasdaq debut today (August 6, 2026), pricing its shares at $18 each.

The lead drug candidate is BHB 1893, a next-generation oral small molecule cardiac myosin inhibitor being developed to treat obstructive HCM ("oHCM") and non obstructive HCM ("nHCM").

The company expects to initiate LIONHEART-HCM, a global Phase 3 trial of BHB 1893 in oHCM, in the second half of 2026 and NOBLEHEART-HCM, a global Phase 3 trial in nHCM, in the first half of 2027.

BRVE closed Thursday's trading at $29.80, up 65.56%.

ENSC Boosts Liquidity with New Financing

Ensysce Biosciences Inc. (ENSC) on Thursday completed the acquisition of Cy Biopharma Inc., a privately held clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain.

The company also announced up to $77 million in private financing, consisting of $21.5 million raised through an initial private placement, $17.1 million in cash and cash equivalents from Cy Biopharma's pre-acquisition convertible note financing, and up to $38.6 million in additional funding upon achievement of clinical trial milestones.

ENSC closed Thursday's trading at $0.52, up 44.83%.

IOVA Records 66% Revenue Growth in Q2

Iovance Biotherapeutics Inc. (IOVA) gained more than 40% on Thursday following its second-quarter financial results.

This commercial biotechnology company focuses on developing and delivering novel polyclonal tumour-infiltrating lymphocyte (TIL) therapies for cancer. Its lead product, Amtagvi, is the first FDA-approved T cell therapy for a solid tumor indication and is indicated for the treatment of adult patients with unresectable or metastatic melanoma.

The company reported Q2 2026 total product revenue of approximately $99 million, up 66% from $60 million in the second quarter of 2025 and 39% from $71 million in the first quarter of 2026.

IOVA closed Thursday's trading at $6.21, up 43.09%.

SGHT Lifts Revenue Outlook

Shares of Sight Sciences Inc. (SGHT) gained more than 27% on Thursday after the company reported second-quarter 2026 financial results, raised its full-year 2026 revenue guidance, and lowered its adjusted operating expense outlook for the year.

Revenue for the second quarter of 2026 was $23.4 million, an increase of 20% compared to $19.6 million in the second quarter of 2025. Net loss narrowed significantly to $4.4 million in Q2 2026, a 63% improvement from $11.9 million in the prior year period. Net loss per share was $0.08, compared to $0.23 in the second quarter of 2025.

Based on the strong quarterly performance, Sight Sciences raised its full-year 2026 revenue guidance to $88 million-$92 million, implying year-over-year growth of 14% to 19%, compared with its previous outlook of $83 million-$89 million. The company also lowered its full-year 2026 adjusted operating expense guidance to $92 million-$94 million, down from its prior forecast of $93 million-$96 million, while still representing a 5% to 7% increase compared with 2025.

SGHT closed Thursday's trading at $7.09, up 27.75%.

MYO Sees 14-19% Revenue Growth in Q3

Myomo Inc. (MYO), a wearable medical robotics company focused on improving functionality for individuals with neurological disorders and upper-limb paralysis, gained more than 20% after reporting second-quarter 2026 financial results.

The company reported Q2 2026 revenue of $11.7 million, a 21% increase compared with the second quarter of 2025, driven by a higher average selling price (ASP) and growth in the number of revenue-generating units.

For the third quarter of 2026, Myomo expects revenue to be in the range of $11.5 million to $12.0 million, representing year-over-year growth of 14% to 19%.

Looking ahead, the company raised its full-year 2026 revenue guidance to $45 million - $47 million, up from its previous outlook of $43 million-$46 million. The updated guidance compares with full-year 2025 revenue of $40.9 million, reflecting continued growth momentum in its wearable medical robotics business.

MYO closed Thursday's trading at $1.31, up 23.58%.

Did you know?

Music-related leisure activities may be associated with a lower risk of dementia in older adults. A study published in the International Journal of Geriatric Psychiatry found that older adults who regularly listened to music or played a musical instrument at least once a week had a 39% and 35% lower risk of developing dementia, respectively, compared with those who did neither activity. (Source: Harvard Health Publishing)

For comments and feedback contact: editorial@rttnews.com

Business News